恶性脑胶质瘤的综合治疗

doi:10.3760/cma.j.issn.1673-422X.2014.11.006

摘要/Abstract

摘要： 恶性脑胶质细胞瘤细胞一般呈浸润性生长，无明显边界，手术完整切除比较困难，且该病理类型对于放化疗敏感性欠佳，故总体治疗疗效不理想，治疗后极易出现局部复发。该病的治疗主要以手术切除配合术后放化疗为主，同时还有靶向治疗、免疫治疗、基因治疗等多种新型治疗方式。

关键词: 神经胶质瘤, 综合疗法

Abstract: Malignant gliomas cells grow invasively with no clear boundary, and a complete resection surgery is very difficult, and the pathological type is not sensitive to radiotherapy and chemotherapy, so the overall treatment effect is not ideal, and this disease is very prone to local recurrence after treatment. The treatment of malignant glioma is mainly composed of surgical resection with postoperative radiotherapy and chemotherapy. Other new treatments include targeted therapy, immune therapy, gene therapy and so on.

Key words: Glioma, Combined modality therapy

董方, 薛金才, 王小虎. 恶性脑胶质瘤的综合治疗[J]. 国际肿瘤学杂志, 2014, 41(11): 816-820.

DONG Fang, XUE Jin-Cai, WANG Xiao-Hu. Multimodality treatment of malignant glioma[J]. Journal of International Oncology, 2014, 41(11): 816-820.

参考文献

［1］温林豹，陈刚．胶质瘤的治疗策略［J］. 中华神经外科疾病研究杂志， 2011, 10(4):382384．［2］ GilRobles S, Duffau H. Surgical management of World Health Organization Grade Ⅱ gliomas in eloquent areas: the necessity of preserving a margin around functional structures［J］. Neurosurg Focus, 2010, 28(2):E8. ［3］张锐，金华，吕中华，等. 胶质瘤手术及辅助技术的进展［J］. 现代肿瘤医学, 2014, 22(4):937941. ［4］黄维, 兰胜民, 曹建忠, 等. 高分级脑胶质瘤术后精确放疗预后影响因素分析［J］.中华肿瘤防治杂志, 2013, 20(18):14181421. ［5］王林, 傅先明. 脑胶质瘤的外科治疗进展［J］. 国际神经病学神经外科学杂志, 2011, 38(3):241244. ［6］桂学宝, 傅先明. 脑胶质瘤综合治疗进展［J］. 立体定向和功能性神经外科杂志, 2013, 26(4):250253. ［7］ Mezger U, Jendrewski C, Bartels M. Navigation in surgery［J］. Langenbecks Arch Surg, 2013, 398(4): 50114. ［8］于圣平, 孙健, 俞凯, 等. 多模态多维影像融合技术在脑胶质瘤手术中的应用［J］.中国现代神经疾病杂志, 2012, 12(6):669674. ［9］许志强. 脑胶质瘤的临床治疗进展［J］. 中国临床神经科学, 2010, 4（18）:431435. ［10］杭春华. 脑胶质瘤的治疗进展［J］. 中国微侵袭神经外科杂志, 2011, 16(9):429432. ［11］ Behbahaninia M, Martirosyan NL, Georges J, et al. Intraoperative fluorescent imaging of intracranial tumors: a review［J］. Clin Neurol Neurosurg, 2013, 115(5): 517528. ［12］ Eyüpoglu IY, Hore N, Savaskan NE, et al. Improving the extent of malignant glioma resection by dual intraoperative visualization approach ［J］. PLoS One, 2012, 7(9):e44885. ［13］ Idoate MA, Diez Valle R, Echeveste J, et al. Pathological characterization of the glioblastoma border as shown during surgery using 5aminolevulinic acidinduced fluorescence［J］.Neuropathology, 2011, 31(6):575582. ［14］ Valdés PA, Kim A, Brantsch M, et al. δaminolevulinic acidinduced protoporphyrin Ⅸ concentration correlates with histopathologic markers of malignancy in human gliomas:the need for quantitative fluorescence guided resection to identify regions of increasing malignancy［J］. Neuro Oncol, 2011, 13(8):846856．［15］ Pickles T, Goodman GB, Rheaume DE, et al. Pion radiation for high grade astrocytoma:results of a randomized study［J］. Int J Radiat Oncol Biol Phys, 1997, 37(3): 491497. ［16］李春田, 刘思杰, 殷增进, 等. 伽马刀治疗脑胶质瘤术后残留60例临床疗效观察［J］. 临床军医杂志, 2013, 41（10）:1095. ［17］ Ruge MI, Kickingereder P, Grau S, et al. Stereotactic iodine125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region［J］. Neuro Oncol, 2013, 15(12):17211731. ［18］肖勇, 刘健, 李玉明. 125I放射性粒子永久植入治疗脑胶质瘤的临床探讨［J］.中国临床神经外科杂志, 2010, 15（11）:676678. ［19］ Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma［J］. Arch Neurol, 2010, 67(3):279283.. ［20］ Bourne TD, Schiff D. Update on molecular findings,management and outcome in lowgrade gliomas［J］. Nat Rev Neurol, 2010, 6(12):695701. ［21］ Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5year analysis of the EORTCNCIC trial［J］. Lancet Oncol, 2009, 10(5):459466. ［22］ Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with highgrade gliomas treated with radiation and temozolomide［J］. Clin Cancer Res, 2011, 17(16):54735480. ［23］汪洋. 高分级胶质瘤化疗治疗进展［J］. 上海医药， 2012, 33(23):1013. ［24］ Guiu S, Taillibert S, Chinot O, et al. Bevacizumab/irinotecan.An active treatment for recurrent high grade gliomas:preliminary results of an ANOCEF Multicenter Study［J］. Rev Neurol(Paris), 2008, 164(67):588594. ［25］ Yung WK, Albright RE, Olson J, et al. A phase Ⅱ study of temozolomide vs.procarbazine in patients with glioblastoma multiforme at first relapse［J］. Br J Cancer, 2000, 83(5):588593. ［26］ Kreisl TN, Kim L, Moore K, et al. Phase Ⅱ trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma［J］. J Clin Oncol, 2009, 27(5):740745. ［27］ Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma［J］.J Clin Oncol, 2009, 27(28):47334740. ［28］ Diaz Miqueli A, Rolff J, Lemm M, et al. Radiosensitisation of U87MG brain tumours by antiepidermal growth factor receptor monoclonal antibodies［J］. Br J Cancer, 2009, 100(6):950958. ［29］李文斌, 陈静, 赵艳杰，等. 尼妥珠单抗联合术后同步放化疗治疗华人恶性胶质瘤的Ⅰ期临床试验［J］. 中国肿瘤临床, 2013, 40(23):14551459. ［30］ Wheeler CJ, Black KL. Vaccines for glioblastoma and highgrade glioma［J］. Expert Rev Vaccines, 2011, 10(6):875886. ［31］冯英楠, 陈菲, 庄伟, 等. 中医药治疗胶质瘤的研究进展［J］. 北京中医药, 2014, 33(2):154157. ［32］杨利辉，石文建，赵喜庆. 鸦胆子油乳对SKMG4 胶质瘤细胞抑制作用研究［J］.中华神经外科疾病研究杂志, 2011, 10(1):3840. ［33］田刚, 雷宁, 王晓娟, 等. 姜黄素对抑制大鼠C6 胶质瘤生成及机制初步研究［J］.现代生物学进展, 2012, 12(4):635637.

[1]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[2]	田津铭, 杨继金. 局部介入联合免疫检查点抑制剂治疗中晚期肝癌研究进展[J]. 国际肿瘤学杂志, 2023, 50(10): 636-640.
[3]	宋佳, 胡钦勇. TACE联合靶向、免疫治疗在BCLC B/C期肝细胞癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 550-554.
[4]	肖楠, 孙鹏飞. 氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361.
[5]	张睿, 冯恩梓, 任艳鑫, 李晓江. 晚期下咽鳞状细胞癌非手术治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(4): 233-236.
[6]	高敏, 冯静, 王丽, 钟海, 文昱婷, 万兵, 张秀伟. 微生物群与肺癌的早期诊断及辅助治疗[J]. 国际肿瘤学杂志, 2022, 49(4): 247-251.
[7]	孔春禹, 孙鹏飞. SLC7A11与胶质瘤[J]. 国际肿瘤学杂志, 2022, 49(10): 604-607.
[8]	狄伟华, 赵雪梅. DNA损伤修复在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 635-638.
[9]	郭世豪, 任叶青, 郭庚. 脑胶质瘤血管生成拟态分子机制[J]. 国际肿瘤学杂志, 2021, 48(6): 362-365.
[10]	王宪伟, 史美燕, 王凤芹, 齐福, 王朝喆, 周飞. TSA上调miR-4298靶向抑制PADI4表达在诱导U251细胞凋亡中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 193-199.
[11]	程翠, 孙利, 蔡丰, 江浩, 孙谦. 手术联合放化疗治疗晚期下咽癌的生存及安全性评价[J]. 国际肿瘤学杂志, 2021, 48(2): 80-85.
[12]	张雯, 胡伟国, 宋启斌. 3D-ASL与DCE-MRI在脑胶质瘤复发与放射性脑坏死鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(10): 631-634.
[13]	赵聪选, 于韬. 胶质瘤相关基因的挖掘及预测[J]. 国际肿瘤学杂志, 2020, 47(5): 293-296.
[14]	郑歆, 陈晓品. 我国口咽癌与HPV的关系[J]. 国际肿瘤学杂志, 2020, 47(3): 164-168.
[15]	南阳, 钟跃. 长非编码RNA在神经胶质瘤研究中的新进展[J]. 国际肿瘤学杂志, 2020, 47(2): 98-102.